After accumulation, acceleration. Timing appears favorable to go long in shares of Cellectis and to anticipate an exit of the trading range on the upside. Investors have an opportunity to buy the stock and target the € 10.75.
The company usually posts poor financials for mid or long term investments.
The company has poor fundamentals for a short-term investment strategy.
The share is getting closer to its long-term support in weekly data, at EUR 7.38, which offers good timing for buyers.
Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 7.38 support.
Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The company has insufficient levels of profitability.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
With an enterprise value anticipated at 3.71 times the sales for the current fiscal year, the company turns out to be overvalued.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The technical configuration over the long term remains negative on the weekly chart below the resistance level at 11.41 EUR
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.